--- title: "Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 6.9% - Should You Sell?" description: "Recursion Pharmaceuticals (NASDAQ:RXRX) shares fell 6.9% to $6.14, with trading volume down 68% from average levels. Analysts have mixed ratings, with KeyCorp lowering its price target from $12 to $10" type: "news" locale: "en" url: "https://longbridge.com/en/news/231272885.md" published_at: "2025-03-10T21:04:58.000Z" --- # Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 6.9% - Should You Sell? > Recursion Pharmaceuticals (NASDAQ:RXRX) shares fell 6.9% to $6.14, with trading volume down 68% from average levels. Analysts have mixed ratings, with KeyCorp lowering its price target from $12 to $10, while Needham maintains a buy rating at $11. The company reported a quarterly loss of $0.53 per share, missing estimates, and revenue of $4.60 million, significantly below expectations. Institutional investors hold 89.06% of the stock, and the company is involved in several clinical trials for various treatments. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) dropped 6.9% on Monday . The company traded as low as $6.01 and last traded at $6.14. Approximately 8,113,213 shares changed hands during mid-day trading, a decline of 68% from the average daily volume of 25,409,162 shares. The stock had previously closed at $6.59. ## Analyst Ratings Changes - Sudden Ascent: Is Recursion Pharmaceuticals NVIDIA’s AI Favorite? RXRX has been the topic of several research analyst reports. KeyCorp cut their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a report on Wednesday, January 8th. Needham & Company LLC reissued a "buy" rating and set a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th. Cowen restated a "hold" rating on shares of Recursion Pharmaceuticals in a report on Friday, February 28th. Finally, Leerink Partners decreased their price target on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research report on Friday, February 28th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, Recursion Pharmaceuticals has an average rating of "Hold" and an average target price of $8.25. **Check Out Our Latest Report on RXRX** ## Recursion Pharmaceuticals Price Performance - Biotechs on the Brink: 2 Stocks With Huge Potential The stock's 50 day moving average is $7.64 and its two-hundred day moving average is $7.07. The stock has a market capitalization of $2.40 billion, a PE ratio of -4.01 and a beta of 0.85. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings data on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.17). The firm had revenue of $4.60 million during the quarter, compared to analyst estimates of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. Recursion Pharmaceuticals's revenue for the quarter was down 57.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.42) earnings per share. As a group, sell-side analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year. ## Institutional Investors Weigh In On Recursion Pharmaceuticals - AI Pharma: 2 Paths to AI-Powered Drug Investment Several hedge funds and other institutional investors have recently made changes to their positions in the business. Decker Retirement Planning Inc. purchased a new position in Recursion Pharmaceuticals in the fourth quarter valued at approximately $26,000. Private Trust Co. NA acquired a new stake in Recursion Pharmaceuticals during the 4th quarter worth $27,000. GAMMA Investing LLC lifted its position in Recursion Pharmaceuticals by 1,979.2% in the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock valued at $35,000 after acquiring an additional 4,948 shares during the last quarter. Farther Finance Advisors LLC boosted its stake in Recursion Pharmaceuticals by 176.9% in the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company's stock valued at $42,000 after acquiring an additional 4,091 shares in the last quarter. Finally, KBC Group NV increased its position in shares of Recursion Pharmaceuticals by 79.9% during the third quarter. KBC Group NV now owns 7,602 shares of the company's stock worth $50,000 after purchasing an additional 3,377 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company's stock. ## Recursion Pharmaceuticals Company Profile (Get Free Report) Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. ## See Also - Five stocks we like better than Recursion Pharmaceuticals - Following Congress Stock Trades - How to Protect Your Portfolio When Inflation Is Rising - Stock Splits, Do They Really Impact Investors? - 3 Tech Stocks Defying Sector Weakness and Thriving in 2025 - What Are the U.K. Market Holidays? How to Invest and Trade - Despite Challenges Novo Nordisk Plans to Crush GLP-1 Competitors *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.* ## Should You Invest $1,000 in Recursion Pharmaceuticals Right Now? Before you consider Recursion Pharmaceuticals, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list. While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [RXRX.US - Recursion Pharmaceuticals](https://longbridge.com/en/quote/RXRX.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Lux Capital 籌集了 15 億美元，創下其有史以來最大的基金規模 | Lux Capital 已經完成了 15 億美元的第九隻基金，標誌着其迄今為止最大的基金。儘管美國新的風險投資基金數量有所下降，但有限合夥人仍被 Lux 在國防技術和人工智能領域的成功投資所吸引。該公司支持了諸如 Anduril 和 App | [Link](https://longbridge.com/en/news/271833261.md) | | Cathie Wood 的 ARK 投資公司購買了 Recursion Pharmaceuticals, Inc. (RXRX) 的 75.5 萬股股票 | Cathie Wood 的 ARK 投資於 2025 年 12 月 19 日購買了 755,000 股 Recursion Pharmaceuticals, Inc.（NASDAQ:RXRX）。Recursion 被認為是 12 只最佳基因 | [Link](https://longbridge.com/en/news/271173852.md) | | 董事 Blake Borgeson 報告了出售 Recursion Pharmaceuticals 普通股的情況 | 布雷克·博爾赫森（Blake Borgeson），Recursion Pharmaceuticals Inc. 的董事，已報告出售該公司的普通股。完整的文件可以通過提供的鏈接訪問。此新聞簡報由公共技術公司（Public Technologi | [Link](https://longbridge.com/en/news/271989611.md) | | 美股異動速遞：Abits 大漲 163.29%，Rackspace Tech 漲 64.49%，Twin Vee PowerCats 跌 54.59% | 美股市場概況當前市場呈現出明顯的強弱分化，科技股和小盤股的表現尤為突出。Abits 的暴漲引發了市場的廣泛關注，成交量大幅放大，顯示出資金的強烈介入。與此同時，部分股票如 Twin Vee PowerCats 和 Interactive S | [Link](https://longbridge.com/en/news/276477237.md) | | Recursion Pharmaceuticals, Inc.（納斯達克股票代碼：RXRX）被券商給予平均 “持有” 評級 | Recursion Pharmaceuticals, Inc.（納斯達克代碼：RXRX）獲得了六位分析師的共識評級為 “持有”。一位分析師將其評級為賣出，三位為持有，二位為買入。12 個月的平均目標價格為 9.40 美元。最近的內部交易包括 | [Link](https://longbridge.com/en/news/272181644.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.